Results 301 to 310 of about 249,854 (357)
Some of the next articles are maybe not open access.
Hospital Medicine, 2000
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Antiplatelet therapies in diabetes
Diabetic Medicine, 2020AbstractCardiovascular complications remain the main cause of mortality and morbidity in diabetes. This is related to advanced vascular pathology in this population, together with an enhanced thrombotic environment. The increased risk in thrombosis is secondary to platelet hyper‐reactivity and increased levels and/or altered activity of coagulation ...
R. C. Sagar, K. M. Naseem, R. A. Ajjan
openaire +2 more sources
Blood reviews, 2020
Platelets are central to inflammation-related manifestations of cardiovascular diseases (CVD) such as atherosclerosis. Platelet-activating factor (PAF), thrombin, thromboxane A2 (TxA2), and adenosine diphosphate (ADP) are some of the key agonists of ...
R. Lordan, A. Tsoupras, I. Zabetakis
semanticscholar +1 more source
Platelets are central to inflammation-related manifestations of cardiovascular diseases (CVD) such as atherosclerosis. Platelet-activating factor (PAF), thrombin, thromboxane A2 (TxA2), and adenosine diphosphate (ADP) are some of the key agonists of ...
R. Lordan, A. Tsoupras, I. Zabetakis
semanticscholar +1 more source
Antiplatelet therapy in children
Thrombosis Research, 2006Platelets are essential for the maintenance of vascular integrity and control of bleeding at sites of injury, but they are also implicated in the progression of atherosclerotic lesions and arterial vascular thrombosis. The use of antiplatelet drugs for the primary and secondary prevention of cardiovascular and cerebrovascular thromboses in adult ...
Israels, Sara J., Michelson, Alan D.
openaire +3 more sources
Pharmacogenetics of Antiplatelet Therapy
Current Atherosclerosis Reports, 2014There has been substantial progress toward understanding and investigating the specific genetic factors that influence interindividual variations in platelet-directed therapy. There has also been substantial progress toward better understanding of the pharmacogenetics of drug metabolism and phamacodynamic response to platelet antagonists.
Patrick L, Daly, Richard C, Becker
openaire +2 more sources
Antiplatelet drug nonresponsiveness
American Heart Journal, 2008The response to most medication, including antiplatelet drugs, is highly variable between individuals. Observational studies have shown that nonresponders to antiplatelet agents appear to have an increased incidence of vascular events. This review article reviews the background, mechanisms, and evidence in support of the clinical significance of this ...
Patrick, Gladding +4 more
openaire +2 more sources
Australian and New Zealand Journal of Medicine, 1998
AbstractAspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. Secondary prevention with chronic aspirin therapy is also indicated for patients with stable angina.Aspirin inhibits cyclo‐oxygenase‐I, a key enzyme in the biosynthetic pathway leading to the production of thromboxane A2.
H D, White, J K, French, C J, Ellis
openaire +2 more sources
AbstractAspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. Secondary prevention with chronic aspirin therapy is also indicated for patients with stable angina.Aspirin inhibits cyclo‐oxygenase‐I, a key enzyme in the biosynthetic pathway leading to the production of thromboxane A2.
H D, White, J K, French, C J, Ellis
openaire +2 more sources
Antiplatelet effect of demethyldiisoeugenol
Canadian Journal of Physiology and Pharmacology, 1996A semisynthetic chemical compound, demethyldiisoeugenol, concentration dependently inhibited platelet aggregation and ATP release stimulated by thrombin (0.1 U/mL), platelet-activating factor (2 ng/mL), arachidonic acid (100 microM), collagen (10 micrograms/mL), and U46619 (1 microM) in rabbit washed platelets.
C H, Liao, F N, Ko, Y H, Kuo, C M, Teng
openaire +2 more sources
Current Atherosclerosis Reports, 2011
Advances in antiplatelet therapy have significantly improved outcomes in patients with ischemic heart disease. Thienopyridines remain a cornerstone of therapy along with aspirin. Recently, concerns have been raised about the use of clopidogrel due to its pharmacokinetic and pharmacogenetic interpatient variability.
Luke, Kim +3 more
openaire +2 more sources
Advances in antiplatelet therapy have significantly improved outcomes in patients with ischemic heart disease. Thienopyridines remain a cornerstone of therapy along with aspirin. Recently, concerns have been raised about the use of clopidogrel due to its pharmacokinetic and pharmacogenetic interpatient variability.
Luke, Kim +3 more
openaire +2 more sources
Antiplatelet therapy in cardiology
Clinical Medicine (Russian Journal), 2016Platelets are important components of hemostasis and play a key role in the formation of atherothrombosis. Rupture or erosion of atherosclerotic plaque gives rise to a thrombus with the involvement of platelets. Antiplatelet agents are instrumental in preventing the development of atherothrombosis of different localization, including coronary arteries.
L V, Popova +2 more
openaire +2 more sources